242 related articles for article (PubMed ID: 25624996)
1. Adiponectin serum level in chronic hepatitis C infection and therapeutic profile.
Peta V; Torti C; Milic N; Focà A; Abenavoli L
World J Hepatol; 2015 Jan; 7(1):44-52. PubMed ID: 25624996
[TBL] [Abstract][Full Text] [Related]
2. Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumour necrosis factor-alpha in chronic hepatitis C patients.
Durante-Mangoni E; Zampino R; Marrone A; Tripodi MF; Rinaldi L; Restivo L; Cioffi M; Ruggiero G; Adinolfi LE
Aliment Pharmacol Ther; 2006 Nov; 24(9):1349-57. PubMed ID: 17059516
[TBL] [Abstract][Full Text] [Related]
3. Decreased plasma adiponectin concentrations are closely related to steatosis in hepatitis C virus-infected patients.
Petit JM; Minello A; Jooste V; Bour JB; Galland F; Duvillard L; Verges B; Olsson NO; Gambert P; Hillon P
J Clin Endocrinol Metab; 2005 Apr; 90(4):2240-3. PubMed ID: 15644404
[TBL] [Abstract][Full Text] [Related]
4. Correlation of serum adiponectin levels and hepatic steatosis in hepatitis C virus genotype 1 infection.
Kara B; Gunesacar R; Doran F; Kara IO; Akkiz H
Adv Ther; 2007; 24(5):972-82. PubMed ID: 18029322
[TBL] [Abstract][Full Text] [Related]
5. Association of serum adipocytokines with insulin resistance and liver injury in patients with chronic hepatitis C genotype 4.
Khattab MA; Eslam M; Aly MM; Shatat M; Hussen A; Moussa YI; Elsaghir G; Abdalhalim H; Aly A; Gaber S; Harrison SA
J Clin Gastroenterol; 2012; 46(10):871-9. PubMed ID: 22664476
[TBL] [Abstract][Full Text] [Related]
6. The relationship between serum adiponectin and steatosis in patients with chronic hepatitis C genotype-4.
Ashour E; Samy N; Sayed M; Imam A
Clin Lab; 2010; 56(3-4):103-10. PubMed ID: 20476641
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms and significance of liver steatosis in hepatitis C virus infection.
Negro F
World J Gastroenterol; 2006 Nov; 12(42):6756-65. PubMed ID: 17106922
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus infection and liver steatosis.
Ramalho F
Antiviral Res; 2003 Oct; 60(2):125-7. PubMed ID: 14638408
[TBL] [Abstract][Full Text] [Related]
9. Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C.
Miquilena-Colina ME; Lima-Cabello E; Sánchez-Campos S; García-Mediavilla MV; Fernández-Bermejo M; Lozano-Rodríguez T; Vargas-Castrillón J; Buqué X; Ochoa B; Aspichueta P; González-Gallego J; García-Monzón C
Gut; 2011 Oct; 60(10):1394-402. PubMed ID: 21270117
[TBL] [Abstract][Full Text] [Related]
10. [Hepatitis-C infection and hepatic steatosis].
Bosques-Padilla F
Gac Med Mex; 2004; 140 Suppl 2():S73-6. PubMed ID: 15641475
[TBL] [Abstract][Full Text] [Related]
11. Morphological changes in intracellular lipid droplets induced by different hepatitis C virus genotype core sequences and relationship with steatosis.
Piodi A; Chouteau P; Lerat H; Hézode C; Pawlotsky JM
Hepatology; 2008 Jul; 48(1):16-27. PubMed ID: 18570290
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C virus diversity and hepatic steatosis.
Roingeard P
J Viral Hepat; 2013 Feb; 20(2):77-84. PubMed ID: 23301542
[TBL] [Abstract][Full Text] [Related]
13. Metabolic alterations and hepatitis C: From bench to bedside.
Chang ML
World J Gastroenterol; 2016 Jan; 22(4):1461-76. PubMed ID: 26819514
[TBL] [Abstract][Full Text] [Related]
14. Steatosis, insulin resistance and fibrosis progression in chronic hepatitis C.
Castera L
Minerva Gastroenterol Dietol; 2006 Jun; 52(2):125-34. PubMed ID: 16557184
[TBL] [Abstract][Full Text] [Related]
15. Review article: hepatitis C virus-associated steatosis--pathogenic mechanisms and clinical implications.
Adinolfi LE; Durante-Mangoni E; Zampino R; Ruggiero G
Aliment Pharmacol Ther; 2005 Nov; 22 Suppl 2():52-5. PubMed ID: 16225474
[TBL] [Abstract][Full Text] [Related]
16. Development of an in vitro model to study hepatitis C virus effects on hepatocellular lipotoxicity and lipid metabolism.
Koletzko L; Mahli A; Hellerbrand C
Pathol Res Pract; 2018 Oct; 214(10):1700-1706. PubMed ID: 30201523
[TBL] [Abstract][Full Text] [Related]
17. Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C.
Zografos TA; Liaskos C; Rigopoulou EI; Togousidis E; Makaritsis K; Germenis A; Dalekos GN
Am J Gastroenterol; 2008 Mar; 103(3):605-14. PubMed ID: 18190648
[TBL] [Abstract][Full Text] [Related]
18. HCV core-induced nonobese hepatic steatosis is associated with hypoadiponectinemia and is ameliorated by adiponectin administration.
Chang ML; Yeh HC; Tsou YK; Wang CJ; Cheng HY; Sung CM; Ho YP; Chen TH; Yeh CT
Obesity (Silver Spring); 2012 Jul; 20(7):1474-80. PubMed ID: 22421894
[TBL] [Abstract][Full Text] [Related]
19. Transforming Growth Factor β Acts as a Regulatory Molecule for Lipogenic Pathways among Hepatitis C Virus Genotype-Specific Infections.
Patra T; Sasaki R; Meyer K; Ray RB; Ray R
J Virol; 2019 Sep; 93(18):. PubMed ID: 31243135
[TBL] [Abstract][Full Text] [Related]
20. Hepatic steatosis and hepatitis C: Still unhappy bedfellows?
Hwang SJ; Lee SD
J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():96-101. PubMed ID: 21199519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
